Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today. The company’s shares opened today at $50.68.
According to TipRanks, Goonewardene is an analyst with an average return of -3.6% and a 32.31% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Genmab, Iovance Biotherapeutics, and Mersana Therapeutics.
Currently, the analyst consensus on Arcellx Inc is a Strong Buy with an average price target of $80.00.
Based on Arcellx Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $63.15 million and a net profit of $19.84 million. In comparison, last year the company had a GAAP net loss of $38.99 million
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcellx Inc (ACLX) Company Description:
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
